10 Best Building Product Stocks To Watch For 2016: Affymetrix Inc.(AFFX)
Affymetrix, Inc. engages in the development, manufacture, sale, and servicing of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets primarily in the United States, Europe, Japan. The company provides integrated GeneChip microarray platform, which includes disposable DNA probe arrays (chips) consisting of nucleic acid sequences, certain reagents for use with the probe arrays, a scanner and other instruments used to process the probe arrays, and software to analyze and manage genomic or genetic information obtained from the probe arrays. It also offers GeneTitan, an instrument system that runs genotyping and gene expression array plates; and GeneAtlas, an instrument for low-to-medium throughput that provides hybridization and array processing with microwell-based labware, as well as a line of multiplex assays to serve the discovery and the validation markets. In addition, the company provides reagent kits, including ExoSAP-IT fo r a reagent for the clean-up of polymerase chain reaction (PCR) products used in downstream applications, such as DNA sequencing or single-nucleotide polymorphisms analysis; and HotStart-IT reagents that utilize a novel primer binding protein to inhibit primer dimer formation with results in sensitive and consistent amplification for PCR. Its products are used primarily in genotyping and gene expression applications. The company sells its products directly to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies; academic research centers, government research laboratories, private foundation laboratories, and clinical reference laboratories in North America and Europe, as well as through life science supply specialists acting as authorized distributors in Latin America, the Middle East, and Asia Pacific regions. Affyme! trix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.Advisors' Opinion:
- [By James E. Brumley]
And make no mistake - the market wants what CLRX is offering. MedPage Today, a property of Everyday Health, Inc. (NASDAQ:EVDY), Affymetrix Inc. (NASDAQ:AFFX), and Quest Diagnostics Inc. (NYSE:DGX) are just some of the companies that have become paying subscribers to the CollabRx service. If that many reputable names are on board, clearly the service is the real deal.
- [By James E. Brumley]
Every year, more than 100,000 white papers on the topic of cancer and cancer treatments are published. Right now, there are over 500 new cancer drugs in development, and those therapies are part of more than 10,000 different clinical trials currently underway. That's all in addition to the already-approved cancer drugs, and the volumes of information we already know about oncology. What's it mean? It means the cancer-treating energy often suffers from information overload, which in turn means patients aren't getting the best care they could get. The solution is a tool built by a little company called CollabRx Inc. (NASDAQ:CLRX). The validation for that solution comes from much bigger companies Quest Diagnostics Inc. (NYSE:DGX) and Affymetrix, Inc. (NASDAQ:AFFX).
- [By Monica Gerson]
Breaking newsCostco Wholesale (NASDAQ: COST) reported a 5% gain in its April same-store sales. Costco's US same-store sales climbed 5%, while international sales rose 2% in April. Analysts were estimating a 3.2% gain in April same store sales. To read the full news, click here. Dish Network (NASDAQ: DISH) reported an 18% drop in its first-quarter profit. Dish's quarterly earnings slipped to $175.9 million, or $0.38 per share, versus $215.6 million, or $0.47 per share, in the year-ago period. To read the full news, click here. Affymetrix (NASDAQ: AFFX) and Leica Biosystems announce the launch of Affymetrix' fully automated! RNA in s! itu hybridization assays ViewRNATM eZ Assays on the Leica BOND RX staining platform. To read the full news, click here. Priceline Group (NASDAQ: PCLN) reported a 36% gain in its first-quarter earnings. Priceline's quarterly profit surged to $331.2 million, or $6.25 per share, versus a year-ago profit of $244.3 million, or $4.76 per share. To read the full news, click here.
Posted-In: Morgan Stanley US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
- [By Bryan Murphy]
What do Quest Diagnostics Inc. (NYSE:DGX) and Affymetrix, Inc. (NASDAQ:AFFX) know that the rest of the healthcare industry doesn't seem to know yet? In simplest terms, AFFX and DGX seem to have come to grips with the reality that there's so much information out there in the diagnostic and treatment world that caregivers are actually stumbling over it. The end result is not only care that's not better than it was in the recent past, but perhaps less effective than it used to be simply because of information overload and/or a lack of understanding of what to do with all sorts of data.
source from Top Stocks For 2015:http://www.topstocksblog.com/10-best-building-product-stocks-to-watch-for-2016.html